HomeSearch for 'Patients'

Patients - News and Articles about commonly prescribed drugs

Rituxan Labeling Up to date With Observe Up Remedy Data for Sufferers With GPA/MPA

Posted in News on 20th October 2018

October 19, 2018

Rituxan is a CD20-directed cytolytic antibody

Rituxan is a CD20-directed cytolytic antibody

The Food and Drug Administration (FDA) has approved updated labeling for Rituxan (rituximab; Genentech) to include information on follow up treatment for patients with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) who have achieved disease control with induction therapy. Rituxan, a CD20-directed cytolytic antibody, was initially approved for GPA and MPA, in combination with glucocorticoids, in 2011.

The approval for follow up treatment was based on data from an open-label, prospective, active-controlled study (MAINRITSAN) involving 115 patients in disease remission (86 with GPA, 24 with MPA, 5 with renal-limited ANCA-associated vasculitis). Patients were randomized to receive azathioprine or rituximab; the primary endpoint of the study was the occurrence of major relapse, defined by the reappearance of clinical or laboratory signs of vasculitis activity that could lead to organ failure or damage, or could be life-threatening, through month 28.

Related Articles

Results showed the observed cumulative incidence rate of first major relapse during the 28 months was lower in patients treated with rituximab compared with azathioprine (5% vs 29%, respectively). In addition, the safety profile was found to be consistent with that previously seen in this patient population.

“Options for continued treatment in GPA and MPA, chronic autoimmune diseases in which patients experience periods of flares, are currently limited,” said Sandra Horning, MD, chief medical officer and head of Global Product Development. “As part of our commitment to support people living with rare diseases, we are pleased to provide updated prescribing information for Rituxan to help physicians make more informed decisions about therapeutic options for patients who have achieved disease control with induction treatment.”

For more information visit Gene.com.

Scroll down to see the next article

Lyra Therapeutics broadcasts presentation of Section 1 medical knowledge for LYR-210 in CRS sufferers

Posted in News on 13th October 2018

Lyra Therapeutics, Inc., a clinical-stage biotechnology firm creating medicines exactly designed to focus on ear, nostril and throat (ENT) ailments, at this time introduced the presentation of Section 1 medical knowledge for the corporate’s lead therapeutic, LYR-210, for power rhinosinusitis (CRS), a debilitating illness brought on by irritation of the paranasal sinus tissues that impacts roughly 27 million folks, or 11% of the grownup inhabitants within the U.S. The Section 1 knowledge for LYR-210 was chosen for an oral presentation as a prime fifteen summary on the 64th Annual Assembly of the American Rhinologic Society, which passed off October 5-6 in Atlanta.

Within the Section 1 research, CRS sufferers who haven’t had sinus surgical procedure obtained in-office bilateral administration of LYR-210, deep into the sinonasal passages, designed to offer long-acting launch of anti-inflammatory steroid via a proprietary, biodegradable polymeric matrix on the web site of illness. Outcomes from the Section 1 research confirmed that LYR-210 was secure and properly tolerated and the CRS sufferers achieved important enchancment within the sinonasal end result take a look at (SNOT-22) after single administration of LYR-210, which supplied 24 weeks of steady anti-inflammatory drug therapy. SNOT-22 is a symptom-based questionnaire that can be utilized to evaluate nasal obstruction and the impression of sinonasal illness. Outcomes from the Section 1 research assist the development of LYR-210 right into a Section 2 research that’s deliberate to start within the first half of 2019.

“There may be important unmet medical want for brand spanking new therapy choices for sufferers with power rhinosinusitis which impacts tens of millions of sufferers of their every day lives. These outcomes from the Section 1 research present that LYR-210 provides a promising new front-line method to ship 24 weeks of steady anti-inflammatory remedy to the tight anatomy of the sinonasal tissues and demonstrates speedy, clinically significant and sturdy outcomes for sufferers with this debilitating illness,” mentioned Richard Douglas, M.D., Professor of Surgical procedure at The College of Auckland, New Zealand, and Guide Surgeon at Auckland Metropolis Hospital and the lead investigator within the LYR-210 medical research. “Primarily based on these optimistic Section 1 leads to CRS sufferers, I’m captivated with future medical research with LYR-210 to additional reveal its medical worth and advance this modern remedy for sufferers.”

“We’re very inspired by the outcomes of the Section 1 research with LYR-210, which is the primary time medical knowledge has been reported for a long-acting intranasal steroid therapeutic system in CRS sufferers who haven’t undergone earlier endoscopic sinus surgical procedure. Moreover, it is vitally promising that LYR-210 confirmed early efficacy leads to CRS sufferers each with and with out polyps. We consider these medical outcomes place LYR-210 with a extremely differentiated product profile that gives six months of anti-inflammatory drug remedy with a single administration,” mentioned Maria Palasis, Ph.D., President and Chief Government Officer of Lyra Therapeutics. “Our staff is concentrated on quickly advancing LYR-210 right into a Section 2 research and progressing towards bringing a brand new therapy different to sufferers with CRS.”

On the Annual Assembly of the American Rhinologic Society, Dr. Richard Douglas delivered the oral presentation of the medical outcomes from the Section 1 research of LYR-210 in power rhinosinusitis, together with the next highlights:

  • The Section 1 research enrolled 20 sufferers with reasonable to extreme CRS who failed normal medical administration and have been candidates for endoscopic sinus surgical procedure, however had not undergone earlier endoscopic sinus surgical procedure. CRS sufferers with and with out polyps have been enrolled within the research.
  • All sufferers have been administered long-acting LYR-210 within the outpatient setting of an ENT doctor’s workplace. Within the research, LYR-210 had a 100 p.c success fee for bilateral placement of the LYR-210 transmucosal therapeutic system within the sinonasal passages.
  • Security was the first goal of the Section 1 research, and LYR-210 was secure and well-tolerated with no product-related severe adversarial occasions reported within the research.
  • Within the general research inhabitants, topics skilled clinically significant, statistically important enchancment from baseline of their SNOT-22 scores (P < zero.01), and enchancment was noticed as early as week 1 and continued via week 24. Vital symptom enchancment was additionally achieved within the SNOT-22 rhinological, ear-facial, psychological, and sleep dysfunction subdomains, via week 24.
  • Within the research, no topical nasal spray was utilized together with LYR-210. No sufferers required surgical intervention throughout the 24-week therapy interval.
  • LYR-210 efficiently demonstrated the design parameters of the transmucosal therapeutic system – comprised of drug administered via a biodegradable polymeric matrix – by delivering a customized long-acting formulation of the accredited steroid, mometasone furoate, deep into the sinonasal tissues to offer anti-inflammatory remedy for six months.

Supply:

https://lyratherapeutics.com/

Xarelto Accepted to Cut back Danger of Main Cardiovascular Occasions in Sufferers With CAD, PAD

Posted in News on 13th October 2018

October 12, 2018

Xarelto is the first Factor Xa inhibitor approved for patients with these conditions

Xarelto is the first Factor Xa inhibitor approved for patients with these conditions

Janssen announced that the Food and Drug Administration (FDA) has approved Xarelto (rivaroxaban) to reduce the risk of major cardiovascular (CV) events, such as CV death, myocardial infarction (MI) and stroke, in patients with chronic coronary or peripheral artery disease (CAD/PAD). 

The FDA approval was supported by data from the Phase 3 COMPASS trial (N=27,395) which evaluated Xarelto with or without aspirin for the long-term prevention of major adverse CV events (including MI, stroke, CV death) in patients with chronic CAD or PAD. Results showed a 24% reduction in the risk of major CV events in patients with chronic CAD and/or PAD with Xarelto 2.5mg twice daily + aspirin 100mg once daily, compared with aspirin alone. Specifically, the data showed a 42% reduction in stroke, 22% reduction in CV death, and 14% reduction in MI. 

Patients in the Xarelto + aspirin treatment arm had a significantly higher risk of major bleeding vs the aspirin treatment arm. There was no significant increase, however, in fatal or intracranial bleeds. The sub-analyses of patients with CAD and PAD were published in The Lancet

“As we saw in the COMPASS trial, the dual pathway approach of aspirin and the 2.5mg, twice-daily dose of Xarelto can help significantly reduce the risk of CV events in these populations,” stated Kelley Branchi, MD, MSc, FACC, FSCCT, Associate Professor in Cardiology, University of Washington, Seattle. 

Related Articles

Xarelto, a factor Xa inhibitor, is already approved to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation; for the treatment of deep vein thrombosis (DVT), pulmonary embolism (PE); to reduce the risk of recurrence of DVT and/or PE in patients at continued risk for recurrent DVT and/or PE after completion of initial treatment lasting ≥6 months; and for prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery. It is available in 2.5mg, 10mg, 15mg, and 20mg strength tablets. 

For more information call (800) 526-7736 or visit Janssen.com.

Scroll down to see the next article

Neoadjuvant medical trial of immune checkpoint blockade for melanoma sufferers yields excessive response fee

Posted in News on 9th October 2018

Mixture checkpoint blockade earlier than surgical procedure (neoadjuvant remedy) produced a excessive response fee amongst sufferers with high-risk stage three melanoma, with practically half having no signal of illness at surgical procedure, however a excessive incidence of uncomfortable side effects induced the trial to be closed early.

The part II research was led by researchers at The College of Texas MD Anderson Most cancers Middle. Outcomes of the research, the primary randomized neoadjuvant medical trial of immune checkpoint blockade for melanoma sufferers, are reported in Nature Medication.

Sufferers obtained both the PD-1 inhibitor nivolumab or the mixture of nivolumab and the CTLA-Four checkpoint inhibitor ipilimumab. Every drug blocks a separate off-switch on T cells, liberating the immune system to assault most cancers. All sufferers obtained nivolumab after surgical procedure.

On the mixture arm, eight of 11 (73 %) sufferers had their tumors shrink, 5 (45 %) had no proof of illness at surgical procedure (pathological full response), and 73 % had grade three uncomfortable side effects, inflicting dose delays in 64 % and delaying surgical procedure for some. There have been no grade Four uncomfortable side effects.

Within the nivolumab arm, three of 12 (25 %) had their tumors shrink and had pathological full response, solely eight % had grade three uncomfortable side effects. Two sufferers progressed to stage Four metastatic illness earlier than they might get to surgical procedure.

“On this trial, therapy with single-agent anti-PD-1 was related to modest response charges, and we have been involved that two sufferers on that arm progressed and couldn’t go to surgical procedure,” stated co-first creator Rodabe Amaria, M.D., assistant professor of Melanoma Medical Oncology. “Therapy with mixed checkpoint blockade was rather more efficient, however on the expense of serious toxicity. It’s clear from this trial that we have to additional optimize this therapy method.”

All of those that achieved pathological full response in both arm stay with out proof of illness recurrence. Total survival was 100 % at 24 months within the mixture arm and 75 % within the nivolumab arm.

“The benefit of a neoadjuvant method on this setting is that it allows an interval analysis of the tumor cells after remedy to find out the extent to which these tumor cells responded to the remedy in actual time and predict which sufferers are more likely to expertise sturdy responses going ahead. It additionally gives us the tissue sources to find out why tumors could not reply to remedy and thus tailor therapies going ahead as we be taught extra about resistance,” stated co-senior creator on the research, Michael Tetzlaff, M.D. Ph.D., affiliate professor of Pathology and Translational and Molecular Pathology.

Checkpoint blockade has been efficient towards metastatic melanoma and in lowering the danger of relapse after surgical procedure for high-risk stage three illness. Nonetheless, there may be proof in preclinical fashions that therapy earlier than surgical procedure could also be superior to giving these brokers within the adjuvant setting (after surgical procedure).

Amaria and senior creator Jennifer Wargo, M.D., affiliate professor of Surgical Oncology and Genomic Medication, launched the investigator-initiated trial via MD Anderson’s Moon Pictures Program™, a collaborative effort to speed up the event of scientific discoveries into medical advances that save sufferers’ lives.

Because of the outcomes of this research, the staff re-designed the research to discover the security and efficacy of nivolumab plus relatlimab, an inhibitor of the LAG3 immune checkpoint, a mix that Amaria notes thinks could also be more practical than nivolumab alone with a greater aspect impact profile than therapy with mixed CTLA-Four and PD-1 blockade.

Figuring out biomarkers of response and resistance

“This presurgical platform gives a perfect setting to check biomarkers of response, mechanisms of resistance, and differential results of those two generally used therapy regimens,” stated co-first creator Sangeetha Reddy, M.D., teacher in Most cancers Medication. “On this research we confirmed recognized biomarkers of response and noticed novel biomarkers of therapeutic response that we at the moment are learning additional”.

Evaluation of biopsies and blood samples taken at a number of time factors through the trial revealed:

  • Baseline infiltration of tumors by lymphoid cells and complete mutational burden have been related to response to remedy.
  • Early on-treatment biopsies have been higher predictive of who would reply to each therapies in comparison with baseline biopsies.
  • Molecular analyses utilizing a novel spatial profiling know-how recognized differential abundance of a number of immune markers that correlated with response and/or resistance to neoadjuvant immune checkpoint blockade.
  • T cell receptor sequencing recognized differential patterns in responders versus non-responders to anti-PD-1 remedy versus mixed CTLA-Four and PD-1 blockade. Responders to PD-1 monotherapy confirmed proof of a pre-existing however inhibited T cell repertoire that additional expanded throughout therapy, whereas therapy with mixture remedy was related to extra variable adjustments within the T cell repertoire.

This trial was carried out in parallel to a trial co-led by Christian Clean, M.D., Ph.D., and Ton Schumacher, Ph.D. of the Netherlands Most cancers Institute – who examined using neoadjuvant versus adjuvant (post-surgical) therapy with mixed CTLA-Four and PD-1 blockade in an identical affected person inhabitants.

“The findings of their trial are provocative, demonstrating larger variety of tumor-resident TCRs expanded within the peripheral blood of sufferers receiving neoadjuvant versus adjuvant checkpoint blockade – supportive of what was seen in preclinical fashions – and means that the neoadjuvant method could also be superior.” Wargo stated.

This MD Anderson-led staff is now working with others worldwide in a global neoadjuvant melanoma consortium to harmonize these efforts.

Supply:

https://www.mdanderson.org/newsroom/2018/10/neoadjuvant-combination-checkpoint-blockade-trial-yields-high-response-rates-for-melanoma-patients.html

T-CALM Section 2 scientific research outcomes supply hope for important tremor sufferers

Posted in News on 8th October 2018

Cavion, Inc., a number one scientific stage biotechnology firm dedicated to creating novel therapeutics for folks with neurological ailments, at present introduced promising outcomes of the T-CALM Section 2 scientific trial of its first-in-class T-type calcium channel modulator CX-8998 in important tremor. The corporate plans to current outcomes from this proof-of-concept research as a late-breaking poster on Monday, October eight on the Worldwide Congress of Parkinson’s Illness and Motion Problems® in Hong Kong.

A number of secondary and exploratory endpoints collectively confirmed that therapy with CX-8998 10mg twice day by day resulted in statistically important enchancment versus placebo in actions of day by day dwelling and patient-reported and scientific final result measures, regardless of the research’s main endpoint being missed. Within the research, CX-8998 demonstrated a good security and tolerability profile, with sufferers within the drug therapy arm reporting larger ranges of satisfaction with tremor management remedy in comparison with sufferers on placebo.

“After a long time with out new efficient drug remedy choices, we consider that the neurostabilizing results of CX-8998 present hope for important tremor sufferers,” mentioned Spyros Papapetropoulos, MD, PhD, Cavion’s Government Vice President of Analysis & Growth and Chief Medical Officer. “The information are significantly compelling on condition that about two-thirds of sufferers within the research had been on commonplace of care therapy and important enchancment was achieved with CX-8998 on a number of measures in a research lasting only one month.”

“Important tremor is a problem to deal with, and sufferers typically don’t reply favorably to the prevailing drugs, lots of which have been obtainable for many years,” mentioned Karl Kieburtz, MD, MPH, Professor of Neurology on the College of Rochester Medical Middle. “Cavion’s CX-8998 has a novel mechanism of motion which will present substantive enchancment, and it may very well be an necessary therapeutic contribution above and past what we at present have for important tremor. I stay up for its scientific progress and additional investigation. Higher drugs are wanted to deal with this frequent and disabling motion dysfunction.”

T-CALM was a 28-day, double-blind, placebo-controlled Section 2 proof-of-concept scientific trial in 95 sufferers with average to extreme important tremor, carried out at 25 websites throughout america. Sufferers had been randomized to obtain both placebo or CX-8998 titrated as much as 10mg dosed twice day by day (BID). A majority of topics (64 p.c) added research drug to their current commonplace of care anti-tremor remedy.

The first research endpoint utilizing distant video ranking of the Tremor Analysis Group Important Tremor Ranking Evaluation Scale – Efficiency Subscale (TETRAS-PS), a measure of tremor severity, didn’t meet significance at Day 28 (p=zero.696). In distinction, the identical TETRAS-PS scale rated by the research investigators who noticed the sufferers in particular person resulted in a major enchancment in tremor severity at Day 28 for the CX-8998 handled group in comparison with placebo (p=zero.027). Unbiased evaluation of the video ranking course of uncovered surprising problems in implementation. Cavion is working carefully with the scientific neighborhood to reinforce central video ranking to be used in interventional research.

A number of secondary and exploratory endpoints collectively confirmed statistical significance, with advantages after 28 days of therapy in sufferers receiving CX-8998 10mg twice day by day (BID) in comparison with placebo within the following scales:

  • The TETRAS Actions of Each day Residing (TETRAS-ADL) scale, a measure of tremor affect on day by day actions (p=zero.049)
  • The Clinician International Impression of Enchancment (CGI-I), a measurement of physician-reported world enchancment (p=zero.001)
  • The TETRAS Whole Rating (TETRAS ADL + TETRAS-PS rated by the research Investigators, p=zero.029)
  • The Purpose Attainment Scale (GAS), a measure of progress towards patient-selected objectives (comparable to dressing oneself, writing a sentence, or ingesting out of a cup) (p=zero.034)

As well as, the Affected person International Impression of Change (PGI-C), a measure of patient-reported enchancment, trended in direction of significance favoring CX-8998 (p=zero.089). Kinesia One, an algorithm-based digital measure developed for Parkinson’s illness, did not detect a therapy distinction in Important Tremor sufferers. Further analyses, together with affected person satisfaction with management by anti-tremor remedy and conventional and digital spirography, assist a therapy profit with CX-8998. The drug confirmed a good security and tolerability profile, with nearly all of opposed occasions delicate to average, transient and non-recurring. No main variations between CX-8998 and placebo had been noticed in laboratory values, very important indicators or electrocardiography.

Along with the T-CALM research for important tremor, CX-8998 is at present being studied in T-WAVE, a multi-center Section 2 scientific trial for generalized epilepsy with absence seizures. “The physique of proof supporting our ground-breaking method is quickly increasing,” mentioned Andrew Krouse, President and CEO of Cavion. “Our pipeline of T-type calcium channel therapies extends past tremor to different neurological ailments that share a typical pathophysiology. We stay up for initiating a Section three research in tremor quickly.”​

Supply:

http://www.cavionpharma.com/